EPRX is trading at $7.56 (14.7% up) in after-hours trading, extending strong gains from the regular session amid a broader rally in biotechnology stocks.
- The move appears driven by general bullish sentiment in the biotech sector and a risk-on equity market rather than a fresh company-specific catalyst.
- There have been no new earnings releases, regulatory filings, or clinical updates from Eupraxia Pharmaceuticals today.
- Investors appear to be reacting to the company's prior positive clinical and commercial outlook as momentum continues from the regular trading day.